Additionally, our data suggest that the baseline tumor immune environment may be associated with T-DXd efficacy, with T-DXd treatment tending to increase tumor-infiltrating CD8+ cell densities in patients with gastric cancer. This evidence concerns the gene CD8A and gastric cancer.